The total gross expenditure by major companies on R&D across the Asia Pacific region crossed the $15 billion mark (approx) in 2022. Oncology, neurology, and immunology continue to draw a significant chunk of this investment. With Asia’s growing importance in R&D, the region is poised to play a significant role in shaping the future of pharmaceutical innovation globally.
According to Pharmaprojects, as of January 2022, the top four countries in the region with the most drugs in their pipelines are China, South Korea, Japan and Australia. China leads with 20.8 per cent of the global pipeline, representing 4,189 drugs. South Korea follows closely behind with 13.1 per cent of the pipeline or 2,627 drugs. Japan and Australia have around 10 per cent of the pipeline, with 1,931 and 2,010 drugs, respectively. These four countries demonstrate a strong focus on research and development in the pharmaceutical industry, and their contributions to drug development and innovation are likely to have a significant impact on the future of healthcare.
2022 was a crucial year for many countries as many R&D projects which were halted during the COVID-19-induced slowdown resumed. The region saw an increase in immuno-oncology drugs and many of the top companies expanded their manufacturing footprint with the expansion of new facilities. The average R&D investment was 6-10 per cent of the revenue.
We have featured the top-performing publicly listed companies with more than a billion in revenue from developed markets such as China, Australia, Japan and South Korea. As for Taiwan and Indonesia, we have covered the largest companies in their country.
CSL (Australia)
Bu hikaye BioSpectrum Asia dergisinin May 2023 sayısından alınmıştır.
Start your 7-day Magzter GOLD free trial to access thousands of curated premium stories, and 8,500+ magazines and newspapers.
Already a subscriber ? Giriş Yap
Bu hikaye BioSpectrum Asia dergisinin May 2023 sayısından alınmıştır.
Start your 7-day Magzter GOLD free trial to access thousands of curated premium stories, and 8,500+ magazines and newspapers.
Already a subscriber? Giriş Yap
New South Wales government injects $5M for critical research to address Silicosis crisis
The New South Wales (NSW) government in Australia has committed $5 million in critical funding for silicosis research and a patient support programme for individuals and their families navigating the health risks associated with exposure to silica dust.
Singapore approves new asthma indication for GSK's Trelegy Ellipta
GSK Singapore has announced that the Health Sciences Authority (HSA) has approved a new indication and a new strength for Trelegy Ellipta (fluticasone furoate/umeclidinium/vilanterol 'FF/UMEC/VI') for the maintenance treatment of asthma in patients aged 18 years and older who are not adequately controlled with a combination of a long-acting beta2-agonist (LABA) and an inhaled corticosteroid (ICS).
What's APAC's Recipe of Success in CLINICAL TRIALS MARKET?
Asia-Pacific APAC) is emerging as one of the most promising and resilient markets for clinical trials. According to a report by Clinical Trials Arena, between 2017 and 2022, the region posted growth in clinical trials of around 10 per cent, outstripping growth in other major regions including the US, Europe and the rest of the world RoW). Asia’s growth far exceeded the overall average figure of 5.3 per cent per year. As of 2023, the number of trials reached 14,346 in APAC. Let's delve into the thriving clinical research landscape in the region and explore the trends driving its growth.
From Haematologic to Autoimmune DiseaseThe CAR-T Therapy Second Revolution
Cell and gene therapies have revolutionised the field of medicine, offering new treatment options for patients with various diseases that, by type of disease or severity, were considered untreatable until a few years ago. Rapid technological advancements in genetic and biological engineering and improvements in the quality and standardisation of the manufacturing process are fostering a marked increase in clinical development of these advanced therapies, generally named cell and gene therapies CGT), and they are expected to receive more approvals in the near future.
"Biotech startups still need support in terms of talent, and resources to bring their innovations to market"
Raymond Chow has recently stepped in as the Vice President, Asia Pacific at USheadquartered Cytiva, a global provider of technologies and services for biological therapies, formerly known as GE Healthcare Life Sciences.
"We are exploring opportunities to collaborate with startups and incubators"
Agilent Technologies, a global leader in analytical and clinical laboratory technologies, has named Padraig McDonnell CEO-elect and Chief Operating Officer (COO), succeeding current President and CEO Mike McMullen.
"Australia offers a simple, supportive and robust regulatory process to initiate human trials efficiently"
US-based Uvax Bio, LLC, a spin-off vaccine company from Scripps Research, employs proprietary 1c-SApNP platform technology invented by Dr Jiang Zhu of Scripps Research to develop and commercialise prophylactic vaccines for challenging infectious diseases.
"Regulatory encouragement of advanced tech, including AI will accelerate clinical trials in APAC"
Lokavant Holdings, a US-based clinical trial intelligence technology company provides clinical trial intelligence that enables study teams to make data-driven decisions, as well as risk-based quality management and monitoring services to pharmaceutical companies and contract research organisations (CROs).
What Are the Main Challenges of Modern Clinical Trials?
With a cumulative total of almost 478,000 globally registered trials from the year 2000 to 2023, and growing at around 10 per cent a year in the last five years, the pharmaceutical industry continues to invest in clinical trials as the gold-standard test of therapeutic safety and efficacy. In addition, as the world’s economies and populations move in new directions, the share of non-US trials has reached 54 per cent, a trend that is likely to continue, driven by demographics and epidemiology. As the pace accelerates, trial managers and clinicians face a significant challenge: the explosive growth of data volumes. To succeed in the future, clinical trials need to increase efficiency and better utilise clinical trial data to support informed clinical and operational decision-making.
How APAC Has Turned into Clinical Trial Behemoth
From being a consistent participant in clinical trial conduct worldwide, the APAC has emerged as a major power. A number of causes, including the region's thriving drug development innovation and the ongoing presence of international pharmaceutical corporations conducting multiregional studies, are driving this growth.
